Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00663442 · ClinicalTrials.gov registry record · Phase 4
Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)
A Phase 4 study of ADHD, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 4
- Development phase
- 48
- Enrollment target
- 1
- Study location
NCT00663442: Completed Phase 4 study of ADHD, sponsored by University of Illinois at Chicago.
NCT00663442 is a Phase 4 study of ADHD that has completed, run by University of Illinois at Chicago. The registered enrollment target is 48 participants, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (75% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00663442, a Phase 4 study of ADHD, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 48 participants
- Enrollment target
- 1
- Study location
Study Summary
Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week, parent report measures, clinical interviews, and safety assessments are conducted. Hypothesis: Efficacy and adverse events will be dose dependent. Dopamine Transporter Genotype will predict response
Conditions Studied
Interventions
- DRUG OROS methylphenidate
Study Locations (1)
Illinois
- HALP Clinic, University of Illinois at CHicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 1999-12 |
| Est. Completion | 2004-11 |
| Phase | Phase 4 |
What the finished NCT00663442 record still lists
NCT00663442 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 190-participant average among 75 other ADHD trials with a reported enrollment target (75% lower).
The record links to 1 condition, with ADHD appearing as the primary indexed condition, and to 1 intervention - of which OROS methylphenidate is the first listed.
NCT00663442 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT00663442 about?
NCT00663442 is a clinical study titled "Basic and Clinical Research on Attention Deficit Hyperactivity Disorder (ADHD)". Children between 6-17 are evaluated for ADHD and and a blood sample is obtained for DNA extraction. If eligible, they participate in a 4 week, double blind, placebo controlled trial with weekly switches. In randomized order, children receive 18, 36, 54 mg. OROS methylphenidate and placebo. Each week...
What is the current status of trial NCT00663442?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 48 participants. The study started on 1999-12. Estimated completion is 2004-11.
What conditions does trial NCT00663442 study?
This clinical trial studies the following conditions: ADHD.
What interventions are being tested in trial NCT00663442?
The interventions under investigation include: OROS methylphenidate (DRUG).
Who is sponsoring clinical trial NCT00663442?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00663442 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for ADHD
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00663442's enrollment target sits among peer trials
48 49th of 75 higher than 26 of 75 other ADHD trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other ADHD trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
RECRUITING · Phase 4
-
Evaluating Treatment of ADHD in Children with Down Syndrome
RECRUITING · Phase 4
-
Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHD
RECRUITING · Phase 4
-
AWARE: Management of ADHD in Autism Spectrum Disorder
RECRUITING · Phase 4
-
Single and Combined Effects of Behavioral, Academic, and Medication Treatments for ADHD in the Classroom
ACTIVE NOT RECRUITING · Phase 4
-
A Double-Blind Comparison of Concerta and Placebo in Adults With Attention Deficit Hyperactivity Disorder
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia